Head and Neck Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Head and Neck Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month11 studies across 10 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565Objective response rate (ORR) | Phase 2 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-03-02 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | Study of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-08-12 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | 2026-11-23 | in 95 d | 2026-06-22 |
December 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | 2026-12-30 | in 132 d | 2025-11-17 |
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| BCAX | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2025-08-15 |
| CMPX | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
| PFE | Pfizer | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs) | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2025-11-25 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Head and Neck Cancer
most recently updated first247 studies match. Showing the first 100 of 247 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | 2023-07-06 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | Drug: CHS-114, toripalimab | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | 87 | 2022-12-15 | 2026-09-30 | in 41 d | 2026-08-12 |
| RADX | Radiopharm Theranostics, Ltd | — | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403 | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2026-10-30 | 2027-08-30 | in 375 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT07744126Number of Participants with Adverse Events (AE)s | Phase 2 | Not yet recruiting | Drug: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil | Head and Neck Squamous Cell Carcinoma | 150 | 2026-09-30 | Oct 2029 | ≤ 1,168 d | 2026-08-10 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyNCT06129864Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors | Phase 3 | Recruiting | Drug: volrustomig | Locally Advanced Head and Neck Squamous Cell Carcinoma | 1,145 | 2023-12-14 | 2030-04-17 | in 1,336 d | 2026-08-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06769698Overall Response Rate (ORR) | Phase 2 | Recruiting | Drug: FDC fianlimab+cemiplimab, Cemiplimab, Placebo | Head and Neck Squamous Cell Carcinoma (HNSCC) | 120 | 2026-04-14 | 2028-06-04 | in 654 d | 2026-08-06 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2024-04-03 | 2028-03-20 | in 578 d | 2026-07-30 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | 2024-03-19 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G) | Phase 2 | Active, not recruiting | Drug: tisotumab vedotin, pembrolizumab, carboplatin, cisplatin | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 350 | 2018-06-25 | 2026-03-20actual | — | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment | Phase 2 | Active, not recruiting | Drug: disitamab vedotin | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms | 120 | 2023-11-14 | 2026-03-27actual | — | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| BNTX | BioNTech SE | — | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1NCT04534205Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab | Phase 2/3 | Recruiting | Biological: BNT113, Pembrolizumab | Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | 350 | 2021-01-07 | Apr 2029 | ≤ 984 d | 2026-07-21 |
| BCAX | Bicara Therapeutics | $1.6B | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCNCT06788990Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation. | Phase 2/3 | Recruiting | Drug: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 650 | 2025-01-28 | Apr 2028 | ≤ 619 d | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | 2025-08-22 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| AZN | AstraZeneca | — | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | Drug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma | 13 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsNCT04609566Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria | Phase 2 | Completed | Drug: brentuximab vedotin, pembrolizumab | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 161 | 2021-01-26 | 2026-02-03actual | — | 2026-07-06 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Number of Participants with Adverse Events (AE) | Phase 1 | Recruiting | Drug: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer | 694 | 2021-11-01 | Jul 2027 | ≤ 345 d | 2026-06-23 |
| EXEL | Exelixis | $13.2B | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | Drug: XB010, Pembrolizumab | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC) | 396 | 2024-08-06 | 2026-11-23 | in 95 d | 2026-06-22 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| TEM | Tempus AI | $8.6B | A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)NCT06163534observationalExplore DNA, RNA, immune and other multiomic biomarkers to better understand prognostic or predictive biomarkers and to inform future research for new relevant biomarkers. | — | Recruiting | — | Head and Neck Squamous Cell Carcinoma | 500 | 2024-08-01 | 2028-03-01 | in 559 d | 2026-06-12 |
| AZN | AstraZeneca | — | First in Human Study of AZD9592 in Solid TumorsNCT05647122Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab | Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms | 167 | 2022-12-21 | 2028-08-03 | in 714 d | 2026-06-11 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| KURA | Kura Oncology, Inc. | $1.1B | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)NCT04997902Dose-limiting toxicity (DLT) | Phase 1/2 | Completed | Drug: Tipifarnib, Alpelisib | HNSCC | 45 | 2021-12-07 | 2025-08-29actual | — | 2026-06-05 |
| IBRX | ImmunityBio, Inc. | $8.2B | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNCT07628062Progression-Free Survival (PFS) | Phase 2 | Not yet recruiting | Drug: Nogapendekin Alfa Inbakicept (NAI), Nab-Paclitaxel, Cisplatin · Biological: hAd5-HPV Vaccine (IBRX-042) · Radiation: De-Intensified IMRT, Standard of Care IMRT | HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer | 70 | 2026-07-22 | 2030-12-31 | in 1,594 d | 2026-06-04 |
| PFE | Pfizer | $155.3B | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.NCT04881045Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1) | Phase 1 | Completed | Biological: PF-07257876 | Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer | 29 | 2021-08-18 | 2023-10-24actual | — | 2026-06-02 |
| AZN | AstraZeneca | — | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerNCT04590963results2023-11-18Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set | Phase 3 | Active, not recruiting | Drug: Monalizumab, Cetuximab · Other: Placebo | Squamous Cell Carcinoma of the Head and Neck | 370 | 2020-10-02 | 2022-05-11actual | — | 2026-06-01 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928Objective Response Rate | Phase 2 | Terminatedsponsor's stated reason: After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints. | Biological: Lifileucel, LN-145, LN-145-S1 · Drug: Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed | Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer | 225 | 2019-05-07 | 2026-02-20actual | — | 2026-05-15 |
| ALXO | ALX Oncology Inc. | $288M | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091Phase 1a: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: ALX2004, ALX2004, ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC) | 170 | 2025-08-18 | Jun 2027 | ≤ 314 d | 2026-05-12 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCNCT06295731Phase 2: Objective Response Rate (ORR) | Phase 2/3 | Active, not recruiting | Drug: INBRX-106, Pembrolizumab | Head and Neck Squamous Cell Carcinoma (HNSCC) | 410 | 2024-05-14 | May 2029 | ≤ 1,015 d | 2026-05-08 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487Part A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalation | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046032, Sasanlimab | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer | 6 | 2025-05-08 | 2026-04-23actual | — | 2026-05-08 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08046052 | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 68 | 2023-11-14 | 2026-04-16actual | — | 2026-05-05 |
| PFE | Pfizer | $155.3B | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesNCT06974734Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046037, sasanlimab | Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 8 | 2025-05-06 | 2026-03-20actual | — | 2026-04-23 |
| CMPX | Compass Therapeutics | $430M | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesNCT03881488Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities | Phase 1 | Completed | Drug: CTX-471, Pembrolizumab (KEYTRUDA®) | Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer | 100 | 2019-05-17 | 2025-05-21actual | — | 2026-04-17 |
| FATE | Fate Therapeutics | $307M | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: FT836, Paclitaxel, Cetuximab, Trastuzumab | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma | 113 | 2025-11-04 | Jan 2028 | ≤ 529 d | 2026-04-07 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsNCT03916627Major pathologic response (MPR) at time of surgery for the NSCLC cohorts | Phase 2 | Active, not recruiting | Drug: cemiplimab, Platinum Doublet, fianlimab | Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma | 65 | 2019-07-23 | 2025-03-31actual | — | 2026-04-06 |
| PDSB | PDS Biotechnology Corp. | $12M | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT06790966Overall Survival (OS) | Phase 3 | Active, not recruiting | Combination product: Combination Treatment of PDS0101 and Pembrolizumab · Drug: Pembrolizumab Monotherapy | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma | 252 | 2025-05-30 | Feb 2029 | ≤ 923 d | 2026-04-06 |
| PFE | Pfizer | $155.3B | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerNCT06580938Number of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Biological: PF-07921585, Sasanlimab | Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer | 4 | 2024-11-11 | 2025-07-14actual | — | 2026-03-23 |
| GILD | Gilead Sciences | $177.9B | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565Objective response rate (ORR) | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin | Head and Neck Squamous Cell Carcinoma | 100 | 2025-02-18 | Aug 2026 | ≤ 11 d | 2026-03-02 |
| PFE | Pfizer | $155.3B | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.NCT06546553PART 1: Number of participants with Dose-limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations and not based on safety concerns. | Drug: PF-07826390 · Biological: sasanlimab · Other: SOC (anti-PD-1 + platinum -based chemo) | Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 10 | 2024-09-06 | 2025-10-03actual | — | 2026-02-23 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs) | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | 2024-06-03 | Dec 2027 | ≤ 498 d | 2026-02-19 |
| MGNX | MacroGenics | $261M | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2023-06-13 | 2024-07-04actual | — | 2026-02-09 |
| CUE | Cue Biopharma | $2.4B | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaNCT03978689Dose Limiting Toxicity | Phase 1 | Completed | Drug: CUE-101, KEYTRUDA®, Pembrolizumab | Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma | 80 | 2019-07-30 | 2026-01-04actual | — | 2026-01-22 |
| TNG.PA | Transgene | $231M | A Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5) | Phase 1/2 | Active, not recruiting | Drug: TG4050 | Squamous Cell Carcinoma of Head and Neck | 80 | 2019-12-12 | 2027-12-30 | in 497 d | 2026-01-16 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: sigvotatug vedotin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 6 | 2024-08-21 | 2025-11-18actual | — | 2025-12-15 |
| INCY | Incyte Corporation | $24.7B | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)NCT03358472results2019-09-10Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil | Head and Neck Cancer | 89 | 2017-12-01 | 2018-07-19actual | — | 2025-12-03 |
| PFE | Pfizer | $155.3B | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs) | Phase 2 | Active, not recruiting | Drug: Palbociclib, Cetuximab, Fulvestrant, Letrozole | Breast Cancer, Head and Neck Cancer | 35 | 2022-07-07 | 2026-12-31 | in 133 d | 2025-11-25 |
| GILD | Gilead Sciences | $177.9B | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaNCT04854499results2025-11-19Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study | Drug: Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab | Head and Neck Squamous Cell Carcinoma | 193 | 2021-09-07 | 2024-10-02actual | — | 2025-11-19 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsNCT05812027observationalFrequency of subjects with TAA expression, HLA typing and HLA loss. | — | Active, not recruiting | Diagnostic test: Tumor and HLA Profiling | Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma | 1,150 | 2023-06-26 | 2026-01-01 | — | 2025-11-17 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | Biological: TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201 | Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma | 840 | 2024-05-06 | 2026-12-30 | in 132 d | 2025-11-17 |
| BOLT | Bolt Biotherapeutics, Inc. | $6M | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesNCT06052852Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BDC-3042, Cemiplimab | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma | 17 | 2023-10-11 | 2025-08-01actual | — | 2025-11-17 |
| TEM | Tempus AI | $8.6B | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437results2025-10-29Overall Response Rate (ORR) - Independent Central Review (ICR) | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: Niraparib | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 22 | 2022-03-15 | 2024-08-06actual | — | 2025-10-29 |
| NANO.PA | Nanobiotix | — | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339[Dose Escalation Part]: Determination of the Recommended Dose | Phase 1 | Active, not recruiting | Drug: NBTXR3, Nivolumab, Pembrolizumab · Radiation: SABR | Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder) | 145 | 2019-01-16 | 2027-04-30 | in 253 d | 2025-10-24 |
| PDSB | PDS Biotechnology Corp. | $12M | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCNCT04260126Best Overall Response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) of the combination of pembrolizumab and PDS0101. | Phase 2 | Completed | Combination product: Pembrolizumab (KEYTRUDA®) and PDS0101 | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 95 | 2021-03-29 | 2025-05-14actual | — | 2025-10-01 |
| BCAB | BioAtla, Inc. | $187M | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604Confirmed Objective Response Rate (ORR) per RECIST v1.1 | Phase 2 | Completed | Biological: Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck | 42 | 2022-12-13 | 2025-09-22actual | — | 2025-09-26 |
| SNY | Sanofi | — | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)NCT05061420results2025-09-22Cohort A1: Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Drug: Pembrolizumab, SAR444245 (Thor-707), Cetuximab | Squamous Cell Carcinoma of Head and Neck | 59 | 2021-10-08 | 2023-07-21actual | — | 2025-09-22 |
| PFE | Pfizer | $155.3B | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07820435 · Biological: Sasanlimab | Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 9 | 2024-02-08 | 2025-01-03actual | — | 2025-09-17 |
| TPST | Tempest Therapeutics | $16M | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab | Phase 1 | Completed | Drug: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab | Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation | 89 | 2020-05-06 | 2024-09-25actual | — | 2025-09-12 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| INCY | Incyte Corporation | $24.7B | Study of INCA 0186 in Subjects With Advanced Solid TumorsNCT04989387Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCA00186, Retifanlimab, INCB106385 | Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies | 57 | 2021-10-04 | 2024-09-19actual | — | 2025-09-02 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) | Phase 2/3 | Active, not recruiting | Drug: Zanzalintinib, Zanzalintinib-matched Placebo · Biological: Pembrolizumab | Head and Neck Squamous Cell Carcinoma | 600 | 2024-06-07 | Aug 2028 | ≤ 742 d | 2025-08-17 |
| BCAX | Bicara Therapeutics | $1.6B | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs | Phase 1 | Recruiting | Drug: BCA101, Pembrolizumab | Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck | 292 | 2020-06-01 | 2026-12-31 | in 133 d | 2025-08-15 |
| INCY | Incyte Corporation | $24.7B | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)NCT02327078results2023-04-26Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: Nivolumab, Epacadostat, Chemotherapy | B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma | 307 | 2014-11-26 | 2020-06-16actual | — | 2025-08-14 |
| MGNX | MacroGenics | $261M | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerNCT02475213results2025-08-11Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab | Phase 1 | Completed | Biological: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma | 146 | Jul 2015 | 2021-08-18actual | — | 2025-08-11 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Biological: XmAb®808, Keytruda® (pembrolizumab) | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer | 60 | 2022-12-14 | 2025-05-20actual | — | 2025-08-07 |
| INCY | Incyte Corporation | $24.7B | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2016-09-14 | 2020-04-30actual | — | 2025-08-05 |
| ALXO | ALX Oncology Inc. | $288M | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)NCT04675333Objective response rate per RECIST 1.1 | Phase 2 | Active, not recruiting | Drug: evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 172 | 2021-05-10 | 2025-03-03actual | — | 2025-08-03 |
| ALXO | ALX Oncology Inc. | $288M | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)NCT04675294Objective response rate per RECIST 1.1 | Phase 2 | Active, not recruiting | Drug: evorpacept, pembrolizumab | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 189 | 2021-04-02 | 2025-03-03actual | — | 2025-08-01 |
| ASND | Ascendis Pharma A/S | — | TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaNCT05980598Major Pathological Response | Phase 2 | Terminatedsponsor's stated reason: The Sponsor made the decision to close enrollment as part of a strategic portfolio review. | Drug: TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ | Head and Neck Neoplasms | 27 | 2023-09-29 | 2025-03-28actual | — | 2025-08-01 |
| MGNX | MacroGenics | $261M | MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596results2025-07-31Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03 | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: vobramitamab duocarmazine | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer | 143 | 2018-11-21 | 2023-03-18actual | — | 2025-07-31 |
| INCY | Incyte Corporation | $24.7B | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE) | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2021-02-03 | 2024-01-22actual | — | 2025-07-11 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| LLY | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | $1.15T | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)NCT05432193Treatment emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: [Ga-68]-PNT6555, [Lu-177]-PNT6555 | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma | 20 | 2022-07-13 | 2023-11-10actual | — | 2025-06-25 |
| BMY | Bristol-Myers Squibb | $134.9B | Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based TherapyNCT03114163observationalOverall Survival | — | Completed | — | Head and Neck Cancer | 485 | 2017-05-12 | 2025-04-28actual | — | 2025-06-18 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| NKTR | Nektar Therapeutics | $2.5B | Study of NKTR 255 in Combination With Cetuximab in Solid TumorsNCT04616196results2025-06-08Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 in Combination With Cetuximab in R/R HNSCC or CRC for Phase 1b Dose Escalation | Phase 1/2 | Completed | Drug: NKTR-255, Cetuximab | Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 25 | 2020-10-30 | 2023-03-30actual | — | 2025-06-08 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| REGN | Regeneron Pharmaceuticals | $76.1B | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT04633278results2025-04-08Confirmed Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: CMP-001, Pembrolizumab | Squamous Cell Carcinoma of Head and Neck | 24 | 2021-01-21 | 2024-01-19actual | — | 2025-05-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Head and Neck Cancer is matched — 20 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Squamous Cell of Head and Neck
- Cancer of Head and Neck
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- HNSCC
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
- Carcinoma, Squamous Cell of the Head and Neck
- Head & Neck Cancer
- Head and Neck Squamous Cell Cancer
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Neoplasms, Head and Neck
- Recurrent Head and Neck Squamous Cell Carcinoma
- Unresectable Head and Neck Squamous Cell Carcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Head and Neck Cancer” (a text search, wider than this page)